JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma: In CTCL cells, Tofacitinib inhibited the level of aberrantly expressed anti-apoptotic miR-21 by blocking JAK3/STAT5 signaling, and STAT5 could directly bind to miR-21 promoter [108].